Transplant News and Research

RSS

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor Pharmaceutical Corp. announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

28 Jun 2010

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

25 Jun 2010

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

We've all experienced the strong heartbeat that accompanies emotions such as fear and rage. But can the body's natural response to these emotions be used to combat heart failure? Results of a study published online today in the journal Circulation Research present a strong case.

25 Jun 2010

Australian youth urged to become organ donors

New research has shown that many young Australians are not having their wishes to donate their organs honored because they fail to discuss these issues with their families beforehand. As a remedial measure Australia's chief medical officer, Professor Jim Bishop has urged more of the young population to come forth about their wishes to donate their organs after death.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.

24 Jun 2010

Amorfix Life Sciences, QED Bioscience sign agreement to develop monoclonal antibodies

Amorfix Life Sciences and QED Bioscience announced today that they have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Under the agreement, QED will generate monoclonal antibodies against several disease specific epitopes on misfolded CD38 protein. The DSE's were identified by Amorfix using their proprietary ProMIS computational platform discovery technology.

24 Jun 2010

USPTO confirms validity of DUSA's key Levulan PDT patent

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office (USPTO) has completed its re-examination of US Patent No. 5,079,262, "Method of detection and treatment of malignant and non-malignant lesions utilizing 5-aminolevulinic acid."

24 Jun 2010

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Merck (Merck is known as MSD outside the United States and Canada) today announced a strategic collaboration between MSD South Africa and Adcock Ingram, a publicly held South African company, to co-promote and distribute a number of established MSD products in South Africa. The products that will be jointly promoted by MSD and Adcock Ingram include over-the-counter (OTC) products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.

24 Jun 2010

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

A team of Cedars-Sinai Regenerative Medicine Institute researchers led by Terrence Town, Ph.D. has been awarded a three-year, $1.47 million grant from the California Institute for Regenerative Medicine to fund research into mechanisms for how human immune systems reject or accept transplanted brain stem cells.

24 Jun 2010

Researchers treat acute kidney injury using cells genetically reprogrammed to produce protein

A protein whose primary role is in the embryonic development of kidneys may play a future role in treating kidney failure. Indiana University School of Medicine researchers have successfully treated acute kidney injury in laboratory experiments using cells that were genetically reprogrammed to produce the protein. The research suggests there could be a potential future treatment using such cells delivered intravenously instead of surgically.

23 Jun 2010

Metabolic syndrome can negatively affect donor's kidney function outcome, study finds

People who donate one of their kidneys experience faster deterioration of their other kidney if they have the metabolic syndrome at the time of donation, a new study finds. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer Inc. announced today that based on discussions with the U.S. Food and Drug Administration (FDA), it will be discontinuing commercial availability of Mylotarg® (gemtuzumab ozogamicin for Injection) (used for the treatment of relapsed acute myeloid leukemia (AML)) in the United States and that it will be voluntarily withdrawing the new drug application (NDA) for Mylotarg effective October 15, 2010.

22 Jun 2010

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Ganciclovir for Injection, USP. Ganciclovir for Injection, USP is therapeutically equivalent to the reference-listed drug Cytovene-IV, which is marketed by Roche Laboratories, Inc.

22 Jun 2010

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

21 Jun 2010

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

The CFIDS Association of America commends the AABB (formerly the American Association of Blood Banking) for its actions to protect the safety of the nation's blood supply by recommending that blood collectors actively discourage potential donors who have been diagnosed by a physician with chronic fatigue syndrome (CFS, also known as chronic fatigue and immune dysfunction syndrome, or CFIDS) from donating blood through the use of donor information materials made available at the donation site.

19 Jun 2010

ThermoGenesis to seek stockholder approval for reverse stock split

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store adult stem cells, said today it will seek stockholder approval of an authorization enabling its Board of Directors in its discretion to affect a reverse stock split in the range of one-for-three to one-for-five shares of common stock in the near future, if required to maintain NASDAQ listing. The authorization will be voted upon during a special meeting of stockholders to be held on Monday, August 9th.

19 Jun 2010

Genzyme signs repurchase agreement with Goldman, Sachs

Genzyme Corporation announced today that it has entered into an agreement with Goldman, Sachs & Co. to repurchase $1 billion of Genzyme common stock under an accelerated stock repurchase program. Proceeds from its recently concluded debt offering will be used to support this first tranche of Genzyme's overall $2 billion share repurchase plan announced in May.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, as compared to other type 2 diabetes medications.

18 Jun 2010

Transplant News and Research

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Cyclosporine treatment develops higher de novo cancer risk in liver transplant patients: Researchers

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

Australian youth urged to become organ donors

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

St. Luke's joins Dr. John Goss in celebration of his 1,000th liver transplantation procedure

Amorfix Life Sciences, QED Bioscience sign agreement to develop monoclonal antibodies

USPTO confirms validity of DUSA's key Levulan PDT patent

MSD enters collaboration with Adcock Ingram to co-promote, distribute products in South Africa

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Researchers treat acute kidney injury using cells genetically reprogrammed to produce protein

Metabolic syndrome can negatively affect donor's kidney function outcome, study finds

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

APP Pharmaceuticals receives FDA approval to market Ganciclovir for Injection, USP

Gamida Cell-Teva Joint Venture's StemEx program receives FDA Fast Track Designation

CFIDS Association applauds AABB for responding to questions about safety of general blood supply

ThermoGenesis to seek stockholder approval for reverse stock split

Genzyme signs repurchase agreement with Goldman, Sachs

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

DURATION-4 study tests superiority of BYDUREON as compared to other type 2 diabetes medications

Industry Focus eBook - Cell biology (5th edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News